Clinical Trial Update: TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating TQB3616 capsules in combination with fulvestrant versus placebo with fulvestrant in previously treated HR-positive, HER2-negative adv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• TQB3616

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: HR-positive,HER2-negative in Advanced Breast Cancer | Phase 3 | Status: COMPLETED